Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22207247 | 0.87 | GAA (0.36) | GAACYP1A2HPGDYTHDC1CYP4F2 | |
| SCHEMBL25171053 | 0.84 | CYP1A2 (0.37) | GAACYP1A2HPGDYTHDC1ALDH1A1 | |
| SCHEMBL1816414 | 0.80 | PKM (0.39) | GAAPKMCYP1A2HPGDMAPK1 | |
| SCHEMBL22552469 | 0.78 | GAA (0.54) | GAAHPGDMAPK1YTHDC1CYP4F2 | |
| SCHEMBL25753217 | 0.77 | GAA (0.49) | GAAPKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL26695907 | 0.76 | ALDH1A1 (0.36) | GAAPKMCYP1A2MAPK1NPSR1 | |
| SCHEMBL31106066 | 0.75 | GAA (0.39) | GAAMAPK1NPSR1CYP4F2CYP4A11 | |
| SCHEMBL25174119 | 0.74 | GAA (0.38) | GAACYP1A2HPGDCYP4F2CYP4A11 | |
| SCHEMBL26695851 | 0.74 | PKM (0.39) | GAAPKMMAPK1NPSR1ALDH1A1 | |
| SCHEMBL22235822 | 0.73 | GAA (0.36) | GAACYP1A2HPGDCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845786-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218290-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218288-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218285-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| WO-2022074534-A1 | COMBINATIONS OF DIHYDROOROTATE DEHYDROGENASE INHIBITORS AND HYPOMETHYLATING AGENTS | JANSSEN BIOTECH, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | disclosed |
| EP-3652179-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-05-20 | — | — | EP | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | GAA 4660/4885PKM 3356/4885CYP1A2 4351/4885 |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | GAA 270/4885PKM 1182/4885CYP1A2 406/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | GAA 331/4885PKM 904/4885CYP1A2 4705/4885 |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | GAA 270/4885PKM 1182/4885CYP1A2 406/4885 |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | GAA 438/4885PKM 1409/4885CYP1A2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.